The programme will highlight current clinical trial options for recurrent glioblastoma, oncological management options for recurrent grade 3 IDH-mutant astrocytoma, and the emerging experience with vorasidenib in the treatment of low-grade gliomas, alongside updates from the INDIGO study.
The conference will also cover relevant topics such as seizure management, psychological support, advanced imaging techniques for gliomas, updates on neurosurgery, offering attendees a comprehensive view of progress across the spectrum of glioma management.
The conference is open to all healthcare professionals involved in the challenges of caring for patients with Low-Grade Gliomas, including and in particular, clinicians, senior nurses and therapy radiographers.
Programme
The preliminary programme is available to view here.
Here you can manage how we can collect data and use cookies for the purpose of analysing website traffic and personalising content within this website but NOT on other websites. You can also manage how Google and other technology partners collect data and use cookies for ad personalisation and measurement.
Accepting recommended settings will set all toggles to 'On'.
More information about cookies and their usage can be found on our Cookie Policy